Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyell Immunopharma, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.22 · Expires 2036-06-09 | Direct | 9,250 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 9,250 · Balance 9,250 F3: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date. |
| Common StockSEC Table I · non-derivative | IndirectGrantor and Trustee | 10,000 |
Reported balance
Holding disclosure · report date 2026-06-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,000 F1: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split. F2: Shares held by the Sumant Ramachandra Rev Trust DTD 01/24/12. The Reporting Person is grantor and trustee of the Sumant Ramachandra Rev Trust DTD 01/24/12. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
F2: Shares held by the Sumant Ramachandra Rev Trust DTD 01/24/12. The Reporting Person is grantor and trustee of the Sumant Ramachandra Rev Trust DTD 01/24/12.
F3: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 20:23 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 9,250 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001439368-26-000002 · form4-06122026_080637.xml · derivative · entry 2 Ramachandra Sumant · CIK 0001439368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,250 Underlying: Common Stock · 9,250 shares Expires 2036-06-09 F3 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:41 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 130,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-25-013705 · form4-05192025_100544.xml · derivative · entry 2 Ramachandra Sumant · CIK 0001439368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2035-05-14 F2 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 22:46 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | PurchaseCommon Stock | 200,000 | $0.58 | $115,220.00 |
DisclosureSEC source: 0001415889-25-008942 · form4-03252025_100313.xml · nonDerivative · entry 1 Ramachandra Sumant · CIK 0001439368 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Grantor and Trustee Disclosed balance after: 200,000 F1 · price: The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.5487 to $0.5879, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range. F2 · ownership.nature: Shares held by the Sumant Ramachandra Rev Trust DTD 01/24/12. The Reporting Person is grantor and trustee of the Sumant Ramachandra Rev Trust DTD 01/24/12. Read SEC document |
| October 31, 2024 Filed Nov 1, 2024 20:56 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 260,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001415889-24-025912 · form4-11012024_081136.xml · derivative · entry 1 Ramachandra Sumant · CIK 0001439368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2034-10-30 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares of common stock subject to the option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month), subject to the reporting person providing service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.